Acceptability and clinical outcomes of levonorgestrel-releasing intrauterine system in the management of abnormal uterine bleeding among perimenopausal women: a prospective interventional study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262119Keywords:
Abnormal uterine bleeding, Levonorgestrel intrauterine system, Perimenopausal women, Menorrhagia, Conservative managementAbstract
Background: The objective of the study was to evaluate the acceptability and clinical outcomes of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the management of abnormal uterine bleeding (AUB) among perimenopausal women.
Methods: This prospective single-arm interventional study without a comparator group study was conducted in a tertiary care teaching hospital from March 2022 to March 2025. A total of 120 perimenopausal women aged 40-55 years presenting with AUB and opting for conservative management were enrolled. LNG-IUS was inserted following appropriate clinical evaluation and counselling. Participants were followed up at 1, 3, 6, and 12 months. Outcomes assessed included bleeding pattern, dysmenorrhea, continuation rate, expulsion, and need for hysterectomy. Data were analyzed using SPSS version 26.
Results: The mean age of participants was 49.21 years, and the majority were multiparous (82.5%). Adenomyosis (53.3%) and fibroid uterus (45.0%) were the predominant etiologies. A progressive reduction in breakthrough bleeding was observed during follow-up. At one year, 30.0% of women achieved amenorrhea, while 69.2% reported light menstrual bleeding. The continuation rate of LNG-IUS at one year was 64.2%, whereas 35.8% of participants opted for hysterectomy. Device expulsion occurred in 2.5% of cases.
Conclusions: LNG-IUS may serve as an effective and acceptable conservative treatment option for perimenopausal women with AUB. It significantly improves bleeding patterns and may reduce the need for surgical intervention in appropriately selected patients.
References
Fraser IS, Critchley HO, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding?. Hum Reprod Update. 2011;17(6):671-84.
Patil S. Menstrual disorders in Indian women: A retrospective study. J Obstet Gynaecol India. 2014;64(5):382-6.
Sharma A, Dogra Y. Trends in abnormal uterine bleeding in northern India. J Midlife Health. 2013;4(1):27-30.
Munro MG, Mast AE, Powers JM, Kouides PA, O'Brien SH, Richards T, et al. The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemia. Am J Obstet Gynecol. 2023;229(1):1-9.
Nazaryan H, Watson M, Ellingham D, Thakar S, Wang A, Pai M, et al. Impact of iron supplementation on patient outcomes for women with abnormal uterine bleeding: a protocol for a systematic review and meta-analysis. Syst Rev. 2023;12(1):121.
Mishra D, Sultan S. FIGO's PALM-COEIN Classification of Abnormal Uterine Bleeding: A Clinico-histopathological Correlation in Indian Setting. J Obstet Gynaecol India. 2017;67(2):119-25.
Nadaleto JO, Ebenur JT, De Macedo DRA, Marrelli MFS, Ferreira LB, Pravatta-Rezende G. Abnormal uterine bleeding control with combined oral contraceptives: a review comparing ethinylestradiol and natural hormones. Rev Bras Ginecol Obstet. 2025;47:e-rbgo84.
Vitale SG, Watrowski R, Barra F, D'Alterio MN, Carugno J, Sathyapalan T, et al. Abnormal Uterine Bleeding in Perimenopausal Women: The Role of Hysteroscopy and Its Impact on Quality of Life and Sexuality. Diagnostics (Basel). 2022;12(5):1176.
Naagar JK, Jaiswal R, Mishra N, Jain R. Role of Levonorgestrel Intrauterine System (LNG-IUS) in the Management of Abnormal Uterine Bleeding (AUB): A Conservative Approach to Preserve the Uterus. J Pharm Bioallied Sci. 2025;17(4):S3177-9.
Heliövaara-Peippo S, Halmesmäki K, Hurskainen R, Teperi J, Grenman S, Kivelä A, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower urinary tract symptoms: a 10-year follow-up study of a randomised trial. BJOG. 2010;117(5):602-9.
Beatty MN, Blumenthal PD. The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability. Ther Clin Risk Manag. 2009;5(3):561-74.
Talukdar B, Mahela S. Abnormal uterine bleeding in perimenopausal women: Correlation with sonographic findings and histopathological examination of hysterectomy specimens. J Midlife Health. 2016;7(2):73-7.
Nicula R, Costin N. Management of endometrial modifications in perimenopausal women. Clujul Med. 2015;88(2):101-10.
Gopinath L, Vaidya R. Prevalence of adenomyosis and associated gynaecological pathologies in hysterectomy samples: a retrospective study. Int J Res Med Sci. 2021;9(9):2606-9.
Koothan V, Vijay A, Maran G, Sreelakshmy. Prevalence and burden of adenomyosis in hysterectomy specimens for benign abnormal uterine bleeding in a tertiary care institute in Pondicherry, India. Int J Reprod Contracept Obstet Gynecol. 2016;5(4):1119-23.
Iniyaval R, Jayanthi B, Lavanya S, Renuka K. A study to assess the prevalence and contributing factors of abnormal uterine bleeding among women admitted in MGMCRI from January to December 2019. Pondicherry J Nurs. 2021;14(1):8-10.
Tariq N, Ayub R, Jaffery T, Rahim F, Naseem F, Kamal M. Efficacy of levonorgestrel intrauterine system (LNG-IUS) for abnormal uterine bleeding and contraception. J Coll Physicians Surg Pak. 2011;21(4):210-3.
Maldonado LY, Sergison JE, Gao X, Hubacher D. Menstrual bleeding and spotting with the Levonorgestrel Intrauterine System (52 mg) during the first-year after insertion: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;222(5):451-68.
Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet. 2007;97(3):190-4.
Blumenthal PD, Dawson L, Hurskainen R. Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet. 2011;112(3):171-8.
Mani P, Chhabra N, Chaudhary N, Setia Chhabra S. Role of LNG-IUS in abnormal uterine bleeding. Int J Reprod Contracept Obstet Gynecol. 2023;12(7):2099-104.
Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79(3):189-93.
Youm J, Lee HJ, Kim SK, Kim H, Jee BC. Factors affecting the spontaneous expulsion of the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet. 2014;126(2):165-9.
Black K, Lotke P, Buhling KJ, Zite NB. Intrauterine contraception for Nulliparous women: Translating Research into Action (INTRA) group. A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women. Eur J Contracept Reprod Health Care. 2012;17(5):340-50.
Lete I, Del Carme Cuesta M, Marín JM, Martínez M, Bermejo A, Arina R. Acceptability of the levonorgestrel intrauterine system in the long-term treatment of heavy menstrual bleeding: how many women choose to use a second device?. Eur J Obstet Gynecol Reprod Biol. 2011;154(1):67-70.
Health Quality Ontario. Levonorgestrel-releasing intrauterine system (52 mg) for idiopathic heavy menstrual bleeding: a health technology assessment. Ont Health Technol Assess Ser. 2016;16(18):1-119.
Downloads
Published
How to Cite
Issue
Section
